Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug

Veradermics, Inc

2026-Q1 EPS reported -$1.32

Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.
Positive Phase 2/3 topline results for VDPHL01 in male pattern hair loss; 12-month data H2 2026.
Enrollment completed in Study '304' (Phase 3, male PHL); topline data H2 2026. Study '306' (female PHL) enrolling.
Raised ~$766.8M gross from IPO and follow-on; cash $390.8M at Mar 31, 2026, expected to fund into 2030.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Veradermics, Inc reported the first quarter ended March 31, 2026 results: net income Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar
Result: reported results

Exact text from the filing

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Veradermics, Inc filing history →

Source: SEC EDGAR

accession 0001827635-26-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.